medigraphic.com
ISSN 1029-3019 (Digital)

2012, Número 03

<< Anterior Siguiente >>

MediSan 2012; 16 (03)


Síndrome de anticuerpos antifosfolípidos

Pouymiró PPO, Pouymiró BY, Pouymiró BI

Idioma: Español
Referencias bibliográficas: 45
Paginas: 429-444
Archivo PDF: 639.05 Kb.


RESUMEN

El síndrome antifosfolípido es un trastorno multisistémico adquirido y una importante causa de trombosis venosas o arteriales, así como también de morbilidad en el embarazo. Puede ser primario o secundario, este último sobre todo en pacientes con lupus eritematoso sistémico, infecciones y consumo de algunas drogas. Se exponen determinados elementos sobre sus manifestaciones clínicas y los criterios de clasificación actualizados para el diagnóstico. El tratamiento se basa en medidas de profilaxis antitrombóticas y control de los factores de riesgo asociados; pero aún muchos aspectos clínicos y de laboratorio concernientes a esta hipercoagulabilidad por la presencia de anticuerpos contra los fosfolípidos, se hallan sujetos a discusión e investigación.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Hughes GRV. Thrombosis, absorption, cerebral disease and the lupus anticoagulant. BMJ. 1983; 287:1088-9.

  2. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemostat. 2006; 4:295-306.

  3. Gorki H, Malinovski V, Stanbridge RDL. The antiphospholipid syndrome and heart valve surgery. Eur J Cardio Thorac Surg. 2008; 3:168-718.

  4. Asherson RA, Cervera R, De Groot PG. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003; 12:530-4.

  5. Hegde VA, Vivas Y, Shah H, Haybron D, Srinivasan V, Dua A, et al. Cardiovascular surgical outcomes in patients with the antiphospholipid syndrome: a case series. Heart Lungs Cir. 2007; 16:423-7.

  6. Giannakopoulos B, Passam F, Rahgozar S, Krilis AS. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood. 2007; 109(2):422-30.

  7. Tripodi A, de Groot PG, Pengo V. Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. J Internal Med. 2011; 270(2):110-22.

  8. Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N, et al. Clinical course of high risk patients diagnosed with antiphospholipid syndrome (APS). J Thromb Haemost. 2010; 8: 237–42.

  9. Rodríguez Santamaría J, Badziak D, Ferreira de Barros M, Luiz Mandelli F, Cavalin LC, Shigueru Sato M. Síndrome antifosfolípide. An Bras Dermatol. 2005;80(3): 3-4.

  10. Devreese K, Hoylaetrs MF. Challenges in the diagnosis of the antiphospholipid syndrome. Clin Chemistry. 2010; 53: 930-40.

  11. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet.1990; 335:1544-7.

  12. Agar C, van Os GM, Mörgelin M β2-Glycoprotein I can exist in two conformations: implications for our understanding of the antiphospholipid syndrome. Blood. 2010; 116:1336–43.

  13. Cohen D, Berger SP, Steup-Beekman GM, Bloemenkamp KW, Bajema IM. Diagnosis and management of the antiphospholipid syndrome. BMJ. 2010; 340:2541.

  14. Avcin T, Cimaz R, Silverman ED, Cervera R, Gattorno M, Garay S. Paediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics. 2008; 122: 1100-7.

  15. 15.Hedge VAP, Vivas Y, Shah H, Haybron D, Srinivasan V, Dua A, Gradman A. Cardiovascular surgical outcomes in patients with the antiphospholipid syndrome- a case series. Heart Lung Cir. 2007;16: 423–7.

  16. Salmon JE, de Groot PG. Pathogenic role of antiphospholipid antibodies. Lupus. 2008;17: 405–11.

  17. 17.Galli M, Reber G, de Moerloose P, de Groot PG. Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost. 2008; 6:399-401.

  18. Pengo V. A contribution to the debate on the laboratory criteria that define the antiphospholipid syndrome. J Thromb Haemost. 2008; 6:1048-9.

  19. Swadzba J, Musial J. More on: the debate on antiphospholipid syndrome criteria. J Thromb Haemost 2009; 7:501-2.

  20. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al. Official communication of the Scientific and Standardization Committee on lupus anticoagulant/phospholipid-dependent antibodies: update of the guidelines for lupus anticoagulant detection. J Thromb Haemost. 2009; 7:1737-40.

  21. De Laat B, Mertens K, de Groot PG. Mechanisms of disease: antiphospholipid antibodies from clinical association to pathological mechanism. Nat Clin Pract Rheumatol. 2008;4: 192-9.

  22. Pierangeli SS, Chen PP, Raschi E, Scurati S, Grossi C, Borghi MO, et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost. 2008; 34:236-50.

  23. Vega Ostertag ME, Pierangeli SS. Mechanisms of aPL-mediated thrombosis: effects of aPL on endothelium and platelets. Curr Rheumatol Rep. 2007; 9:190–7.

  24. Giannakopoulos B, Passam F, Rahgozar S, Krilis S. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood. 2007; 109:422-30.

  25. 25.Urbanus RT, Derksen RHMW, de Groot PG. Current insight into diagnostics and pathophysiology of the antiphospholipid syndrome. Blood Rev. 2008; 22:93-105.

  26. Meroni PL, Gerosa M, Raschi E, Scurati S, Grossi C, Borghi MO. Updating on the pathogenic mechanisms 5 of the antiphos-pholipid antibodies-associated pregnancy loss. Clin Rev Allergy Immunol. 2008; 34:332–7.

  27. 27.Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol. 2011; 7(6): 330-9.

  28. 28.Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. 2005;18(2):1-63.

  29. Giannakopoulos B, Passam F, Ioannou Y, Krilis SA. How we diagnose the antiphospholipid syndrome. Blood. 2009; 113:985-94.

  30. Robertson B, Greaves M. Antiphospholipid syndrome: an evolving story. Blood Rev 2006; 20:201-12.

  31. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemostat. 2009; 7:1737- 40.

  32. Pengo V, Biasiolo A, Bison E, Chantarangkul V, Tripodi A. Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta 2-Glycoprotein I activity. Thromb Res. 2007; 120:127–33.

  33. Pengo V, Biasiolo A, Gresele P, Marongiu F, Erba N, Veschi F, et al. Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J Thromb Haemost 2007; 5: 925–30.

  34. Erkan D, Lockshin. Non-criteria manifestations of antiphospholipid syndrome. Lupus. 2010; 19(4):424–7.

  35. 35.Koniari I, Siminelakis SN, Baikoussis NG, Papadopoulos G, Goudevenos J, Apostolakis E. Antiphospholipid syndrome: its implications in cardiovascular diseases: a review. J Cardiovasc Surg. 2010; 5:101.

  36. Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey R, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010; 69(7):1269-74.

  37. Ruiz Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 2007;57: 1487-95. [PubMed]

  38. Asherson RA. The catastrophic antiphospholipid (Asherson's syndrome) in 2004- a review. Autoimmune Rev. 2005;4: 48-54.

  39. Asherson RA, Cervera R. Microvascular and microangiopathic antiphospholipidassociated syndromes ('MAPS'): semantic or antisemantic? Autoimmun Rev. 2008;7:164–7.

  40. Espinosa G, Cervera R. Antiphospholipid syndrome. Arthritis Res Ther. 2008; 10(6): 230.

  41. 41.Gerosa M, Chighizola C, Meroni PL. Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? Yes (in some cases). Intern Emerg Med. 2008; 3:201–3.

  42. Giannakopoulos B, Krilis SA. How I treat the antiphospholipid syndrome. Blood 2009;114: 2020-30.

  43. Girón González JA, García del Rio E, Rodríguez C, Rodríguez Martorell J, Serrano A. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol. 2004; 31:1560–7.

  44. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease. Chest. 2008; 133(6 Suppl):454-545.

  45. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy Chest. 2008; 133(6 suppl):844-86.




2020     |     www.medigraphic.com